Drug Profile
Research programme: recombinant methioninase - AntiCancer
Alternative Names: AC 9301; AC-9501; METase; Methioninase; ONCase; ONCase-PEG; PEG AC 9501; PEG-methioninase; PEG-rMETase; Recombinant L-methionine gamma-lyase; Recombinant methionine α, γ-lyase; rMETaseLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator AntiCancer
- Developer AntiCancer; Shionogi
- Class Antineoplastics; Carbon sulfur lyases; Polyethylene glycols
- Mechanism of Action DNA methylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Japan (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV, Infusion)